Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-Related Weight Loss
This study has been completed.
Sponsors and Collaborators: Par Pharmaceutical, Inc.
Quintiles
Information provided by: Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier: NCT00637572
  Purpose

Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion formulation, or megestrol acetate oral suspension original formulation


Condition Intervention Phase
HIV Infections
Unintended Weight Loss
Cachexia
Anorexia
AIDS Wasting Syndrome
HIV Wasting Syndrome
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Drug: Megestrol acetate oral suspension 40 mg/mL
Phase II

MedlinePlus related topics: AIDS Weight Control
Drug Information available for: Megestrol acetate Megestrol
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title: A Randomized, Open-Labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-Related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace)

Further study details as provided by Par Pharmaceutical, Inc.:

Primary Outcome Measures:
  • Weight gain [ Time Frame: Baseline, then weekly for 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Bioimpedance analysis [ Time Frame: Baseline, weeks 6 and 12 ] [ Designated as safety issue: No ]
  • Appetite and food intake [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Quality of Life [ Time Frame: 12 weeks plus 30 days after study drug stopped ] [ Designated as safety issue: No ]

Enrollment: 63
Study Start Date: December 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Megestrol acetate oral suspension nanocrystal dispersion formulation
Drug: Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
2: Active Comparator
Megestrol acetate oral suspension micronized formulation
Drug: Megestrol acetate oral suspension 40 mg/mL
Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Capable of and willing to provide informed consent
  • Evidence of HIV infection (either HIV-seropositive, CD4+ T-cell count of ≤350/mm3 or other clinically accepted indicator)
  • An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size, or a recent history of unintentional weight loss of 10% from the subjects baseline
  • Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process
  • Women of childbearing potential had to agree to use effective contraception for the duration of the study and for two weeks after the last dose
  • Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not clinically significant (some exceptions per protocol)
  • Able to read and write in the study related documents translated into the primary local language
  • Capable of and willing to return to the clinic regularly for study visits
  • Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry
  • Capable of completing a 3-day food intake diary with instruction
  • Willing to abstain from any illegal or recreational drug substances for the duration of the trial
  • Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg, steroids [other than those inhaled for treatment of asthmatic conditions], nutritional supplements [other than vitamins or minerals], dronabinol, recombinant human growth hormone, etc.)

Exclusion Criteria:

  • Weight loss due to factors other than AIDS-related wasting
  • Enrollment in any other clinical trial
  • Lack of access to regular meals
  • Women of childbearing potential could not be pregnant or nursing
  • Clinically severe depression evidenced by a baseline score of 17 or more on the Hamilton Depression Rating Scale (GRID-HAMD-17)
  • Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements
  • Intractable or frequent vomiting that regularly interfered with eating
  • Clinically significant diarrhea that would have interfered with absorption of foods or medications
  • Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet
  • History or evidence of thromboembolic events or any first degree relative with a history of thromboembolic events
  • Active AIDS-defining illness or other clinically significant or uncontrolled medical problems
  • Current evidence of or history of diabetes mellitus or hypoadrenalism
  • Systemic treatment with glucocorticoids within the 12 months prior to study entry
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00637572

Locations
United States, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania, United States, 19102
India, Karnataka
M.S. Ramaiah Medical College and Hospital
Bangalore, Karnataka, India, 560054
Kasturba Medical College
Mangalore, Karnataka, India, 575003
Victoria Hospital
Bangalore, Karnataka, India, 560002
India, Maharashtra
Ruby Hall Clinic and Grant Medical Foundation
Pune, Maharashtra, India, 411001
South Africa, Ashwood
St Mary's Hospital
Private Bag, Ashwood, South Africa, 3605
South Africa, Bloemfontein
Genclin Corporation, Clinical Trial Centre
Westdene, Bloemfontein, South Africa, 9301
Quinta-research
Pellissier, Bloemfontein, South Africa, 9317
South Africa, Johannesburg
40 Arthur Hobbs Street
Boksburg, Johannesburg, South Africa, 1466
South Africa, Kwazulu Natal
6 Calypso Centre
Richards Bay, Kwazulu Natal, South Africa, 3900
South Africa, Pretoria
TrialTech Clinical Research
Hatfield, Pretoria, South Africa, 0001
Eastmed Hospital
Eastlynn, Pretoria, South Africa, 0186
Sponsors and Collaborators
Par Pharmaceutical, Inc.
Quintiles
Investigators
Principal Investigator: Jan Fourie, MD 58 Ann Street, Dundee, KZ-Natal 3000, S. Africa
  More Information

Link to published study  This link exits the ClinicalTrials.gov site

Publications of Results:
Wanke C; Gutierrez J; Kristensen A; MacEarchern L. Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States. J Applied Res 2007;7(3):206-216

Responsible Party: Par Pharmaceutical, Inc ( VP Clinical and Medical Affairs )
Study ID Numbers: PAR-002
Study First Received: March 11, 2008
Last Updated: April 1, 2008
ClinicalTrials.gov Identifier: NCT00637572  
Health Authority: United States: Food and Drug Administration

Keywords provided by Par Pharmaceutical, Inc.:
Weight loss
Cachexia
Anorexia
Megestrol acetate oral suspension
Nanocrystal dispersion
Nanocrystal technology
Body weight changes
AIDS wasting
HIV wasting
Emaciation
Megace ES
Megace
Treatment Experienced

Study placed in the following topic categories:
Sexually Transmitted Diseases, Viral
Metabolic Diseases
Signs and Symptoms, Digestive
HIV Wasting Syndrome
Acquired Immunodeficiency Syndrome
Cachexia
Emaciation
Weight Gain
Megestrol
Immunologic Deficiency Syndromes
Virus Diseases
Body Weight
Signs and Symptoms
HIV Infections
Sexually Transmitted Diseases
Weight Loss
Anorexia
Body Weight Changes
Nutrition Disorders
Metabolic disorder
Wasting Syndrome
Retroviridae Infections
Megestrol Acetate

Additional relevant MeSH terms:
RNA Virus Infections
Slow Virus Diseases
Disease
Immune System Diseases
Antineoplastic Agents, Hormonal
Contraceptive Agents
Antineoplastic Agents
Contraceptives, Oral
Physiological Effects of Drugs
Contraceptive Agents, Female
Central Nervous System Stimulants
Reproductive Control Agents
Infection
Pharmacologic Actions
Pathologic Processes
Syndrome
Therapeutic Uses
Lentivirus Infections
Contraceptives, Oral, Synthetic
Central Nervous System Agents
Appetite Stimulants

ClinicalTrials.gov processed this record on January 16, 2009